Literature DB >> 22518269

The Relationship between Pulmonary Dysfunction and Age in Vasospasm Patients Receiving Triple H Therapy.

M Sami Walid1, Gulnur Sahiner, Donald R Robinson, Joe Sam Robinson.   

Abstract

BACKGROUND AND
INTRODUCTION: Triple H therapy is conventionally used to treat vasospasm following sub-arachnoid hemorrhage (SAH) but can sometimes have side effects. In order to investigate pulmonary complications in SAH patients and relationship with age we conducted the following study.
METHODS: The charts of 121 sub-arachnoid hemorrhage patients who underwent clipping or coiling of an aneurysm were retrospectively reviewed. The diagnosis of vasospasm was documented based on Doppler and angiographic findings. All patients with vasospasm received the standard Triple H therapy (hematocrit 33-38%, central venous pressure 10-12 mmHg, systolic blood pressure 160-200 mmHg). We studied intravenous intake, artificial ventilation, hypoxemia/pulmonary edema, postoperative fever, pneumonia and death rates as outcome variables.
RESULTS: Sixty five patients developed vasospasm (15 mild, 23 moderate, 27 severe). These were significantly younger than non-vasospasm patients (51 years vs. 61 years, p=0.004). The average daily intravenous input was 1,730 cc in novasospasm patients, 2,123 cc in the mild vasospasm group, 2,399 cc in the moderate vasospasm group, and 3,040 cc in the severe vasospasm group. Younger patients with moderate to severe vasospasm received more fluids than older patients. Ten patients (8.3%) developed hypoxemia or pulmonary edema. No patient developed hypoxemia/pulmonary edema in the mild vasospasm group and the rates did not show a trend and were not statistically different (7.1%, 0.0%, 13.0%, 11.1%, p>0.05) between vasospasm and non-vasospasm groups. Likewise, postoperative fever and pneumonia rates were not different between the vasospasm and non-vasospasm groups. Using the mean age as a threshold, pulmonary-related complications including death rates tended to be higher in the older group. The rates of postoperative ventilation (30.8% vs. 57.1%, P<0.01) and hypoxemia/pulmonary edema (3.1% vs. 14.3%, P<0.05) rates were statistically higher in the older group. Patients who developed hypoxemia/pulmonary edema in the vasospasm group tended to be younger than those who developed hypoxemia/pulmonary edema in the non-vasospasm group.
CONCLUSION: Younger patients are at a higher risk of developing vasospasm than older patients possibly referable to vessel elasticity and reactive sensitivity factors. Likewise, patients who developed hypoxemia/pulmonary edema in the vasospasm group were younger than in the non-vasospasm group possibly secondary to fluid overload from triple H therapy.

Entities:  

Keywords:  Hypoxemia; Pulmonary Edema; Triple H Therapy; Vasospasm

Year:  2011        PMID: 22518269      PMCID: PMC3317280     

Source DB:  PubMed          Journal:  J Vasc Interv Neurol        ISSN: 1941-5893


  13 in total

1.  Computational modeling of HHH therapy and impact of blood pressure and hematocrit.

Authors:  Joe Sam Robinson; M Sami Walid; Sinjae Hyun; Robert O'Connell; Chris Menard; Brandi Bohleber
Journal:  World Neurosurg       Date:  2010 Aug-Sep       Impact factor: 2.104

Review 2.  Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association.

Authors:  Joshua B Bederson; E Sander Connolly; H Hunt Batjer; Ralph G Dacey; Jacques E Dion; Michael N Diringer; John E Duldner; Robert E Harbaugh; Aman B Patel; Robert H Rosenwasser
Journal:  Stroke       Date:  2009-01-22       Impact factor: 7.914

3.  Intra-aortic balloon pump counterpulsation in the management of concomitant cerebral vasospasm and cardiac failure after subarachnoid hemorrhage: technical case report.

Authors:  P J Apostolides; K A Greene; J M Zabramski; J W Fitzgerald; R F Spetzler
Journal:  Neurosurgery       Date:  1996-05       Impact factor: 4.654

4.  Posterior reversible leukoencephalopathy due to "triple H" therapy.

Authors:  Han Won Jang; Hui Joong Lee
Journal:  J Clin Neurosci       Date:  2010-05-21       Impact factor: 1.961

Review 5.  Transcranial Doppler in cerebral vasospasm.

Authors:  D W Newell; H R Winn
Journal:  Neurosurg Clin N Am       Date:  1990-04       Impact factor: 2.509

6.  Pulmonary function and radiographic abnormalities related to neurological outcome after aneurysmal subarachnoid hemorrhage.

Authors:  A Gruber; A Reinprecht; H Görzer; P Fridrich; T Czech; U M Illievich; B Richling
Journal:  J Neurosurg       Date:  1998-01       Impact factor: 5.115

Review 7.  Cerebral vasospasm following aneurysmal subarachnoid hemorrhage.

Authors:  N F Kassell; T Sasaki; A R Colohan; G Nazar
Journal:  Stroke       Date:  1985 Jul-Aug       Impact factor: 7.914

8.  "Triple h" therapy for aneurysmal subarachnoid haemorrhage: real therapy or chasing numbers?

Authors:  J A Myburgh
Journal:  Crit Care Resusc       Date:  2005-09       Impact factor: 2.159

Review 9.  "Triple-H" therapy for cerebral vasospasm following subarachnoid hemorrhage.

Authors:  Kendall H Lee; Timothy Lukovits; Jonathan A Friedman
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

10.  Pulmonary complications of aneurysmal subarachnoid hemorrhage.

Authors:  Jonathan A Friedman; Mark A Pichelmann; David G Piepgras; Jon I McIver; L Gerard Toussaint; Robyn L McClelland; Douglas A Nichols; Fredric B Meyer; John L D Atkinson; Eelco F M Wijdicks
Journal:  Neurosurgery       Date:  2003-05       Impact factor: 4.654

View more
  1 in total

1.  Effect of HHH-Therapy on Regional CBF after Severe Subarachnoid Hemorrhage Studied by Bedside Xenon-Enhanced CT.

Authors:  Henrik Engquist; Elham Rostami; Elisabeth Ronne-Engström; Pelle Nilsson; Anders Lewén; Per Enblad
Journal:  Neurocrit Care       Date:  2018-04       Impact factor: 3.210

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.